FWY003, FWY003, Placebo to FWY003, FWY003
CFWY003A12201
Phase 2 small_molecule active
Quick answer
FWY003, FWY003, Placebo to FWY003, FWY003 for Geographic atrophy secondary to age-related macular degeneration is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Geographic atrophy secondary to age-related macular degeneration
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active